ESTRO 38 Abstract book

S69 ESTRO 38

prescribed doses and fractionation have been chosen: 24- 31.5 Gy in 8-12 fractions for palliative treatment (5 cases, 15%), 34-52 Gy in 10-20 fractions for adjuvant treatment (20 cases, 59%) and 36,75-60 Gy in 7-30 fractions for radical treatment (9 cases, 26%); the average biological effective dose (BED) was 35.7, 51 and 60.9, respectively. The treatment was mostly delivered with daily fraction and some schedules were accelerated with 2 fractions a day. Acute and late toxicity has been recorded according to CTCAE 4.0. Histology Basal Cell Carcinoma 4 (12%) Squamous Cell Carcinoma 28 (82%) Kaposi Sarcoma 2 (6%) Size, cm Median 3 Range 1-7 Localization Scalp 16 (47%) Ear 6 (18%) Face 7 (21%) Trunk 2 (6%) Extremity 3 (9%) Results At a median follow-up of 12 months (range 3-77,2 months), local control was 97%; in particular no patient treated with an adjuvant BRT HDR after radical surgery had local recurrence and 7 of the 9 lesions (78%) who received a radical dose showed a complete response. In only 4 lesions a partial response was observed, mostly in the palliative group, and just 1 case developed a progression. No severe acute toxicity was recorded; just 32% of the cases presented G2 acute toxicity, recovered within 2 months from the end of BRT. Late G1 toxicity was showed in almost a quarter of the lesions; no G2 or greater late toxicity was recorded. 62% lesions showed an excellent cosmetic impact and just 2 cases resulted in a fair cosmetic outcome. CHARACTERISTICS No of Patients 31 No of lesions 34 Age, years Median 79,6 Range 48,5-102,3 Sex Male 24 (70%) Female 10 (29%)

patients. Results from large multicentre prospective studies are awaited to confirm these observations. PV-0141 Treatment outcomes of HDR brachytherapy for cervical cancer: a comparison of Ir-192 versus Co- 60 T. Tantivatana 1 , R. Kanisa 1 1 Vajira Hospital, Radiation Oncology, Bangkok, Thailand Purpose or Objective To determine and compare treatment outcomes between cobalt-60 (Co-60) and iridium-192 (Ir-192) high dose rate (HDR) brachytherapy in stage IB2–IIIB cervical cancer patients at Department of Radiology, Faculty of Medicine Vajira Hospital, Navamindrahiraj University. Material and Methods A retrospective cohort study of patients diagnosed with cervical cancer and treated with radiotherapy at the Department of Radiation Oncology, Faculty of Medicine Vajira Hospital between 2004 and 2014. Survival rate was analyzed by Kaplan-Meier method and were compared between groups with log-rank test. Multivariate analysis was performed using Cox proportional hazards model. Results A total of 480 patients with cervical cancer and treated with radiotherapy were included, 274 patients for Ir-192 group and 206 patients for Co-60 group. The 2- and 5-year disease-free survival rate in Ir-192 group were 80.4% and 73.1% and in Co-60 group were 82.5% and 74.7%, respectively (p=0.365). Overall survival rates at 2 and 5 years were 89.4% and 77% of the Ir-192 group, and 91.6% and 81.9% in the Co-60 group, respectively (p=0.238). The complications were primarily grade 1 or 2. Grade 3 and 4 complications were found in 13 of 274 and 7 of 206 in Ir- 192 and Co-60 groups, respectively (p=0.23). Grade and clinical stage of cancer significantly affected the survival outcome. Conclusion Cervical cancer patients who were treated with HDR Co- 60 brachytherapy were comparable in survival and toxicity outcomes of those with HDR Ir-192 brachytherapy. Co-60 source has lots of economic advantages over Ir-192 and hence suitable for low resource radiotherapy setting. PV-0142 HDR BRT treatment of non-melanoma skin cancer: outcome and feasibility in a retrospective analysis D. Delishaj 1 , I.C. Fumagalli 1 , R. D'Amico 1 , G. Sangalli 2 , F. Declich 2 , C. Frigerio 2 , C.P. Soatti 1 1 Ospedale Manzoni di Lecco, Department of Radiotherapy, Lecco, Italy ; 2 Ospedale Manzoni di Lecco, Department of Medical Physics, Lecco, Italy Purpose or Objective Non-melanoma skin cancer (NMSC) is the most common malignancy in the white population, comprising about 2-3 million new diagnosis worldwide every year, with an increasing incidence observed in the last decades. High dose rate brachytherapy (HDR-BRT) is an advantageous treatment option both from dosimetric point of view and for patient convenience due to the small number of fractions. The purpose of this study was to evaluate tumour control and toxicity in elderly patients treated with HDR-BRT. Material and Methods A total of 55 patients underwent skin HDR-BRT from October 2007 to July 2018 with Iridium-192 source. 34 lesions in 31 patients affected by NMSC were enrolled; lymphopoietic, breast and benign histology (keloids) were excluded from the analysis. The median age at diagnosis was 79,6 years [48,5-102,4]. A surface flap was customized to the size of each target lesion and the catheters were embedded; every treatment was optimized with 3D planning using CT imaging. Different

Response tu BRT N % radical 9 CR 7 78 PR 1 11 PD 1 11 adjuvant 20 Recurrence 0 palliative 5 CR 2 40 PR 3 60 Acute Toxicity Grade 0 10 30 1 13 38 2 11 32 ≥ 3 0 Late Toxicity 0 26 76 1 8 24 2 0 ≥ 3 0 Cosmetic Result